SV Investment Partners

SV Investments Fund I is a private equity fund managed by SV Investment Partners, LLC, which specializes in buyouts and buildups of lower mid-market companies. Founded in 1999 and headquartered in Greenwich, Connecticut, the firm primarily targets investments in business services sectors, focusing on areas such as marketing services, information technology services, and various other professional services. Within marketing services, the firm emphasizes sectors like database marketing, direct marketing, and media buying. In the information technology space, SV Investment Partners seeks opportunities in software development and IT-enabled business processes. Additionally, the firm invests in information services, including business intelligence and custom publishing. SV Investments Fund I typically engages with companies that have EBITDA ranging from $1 million to $20 million and revenue between $5 million and $100 million, often preferring to co-invest with other firms. The fund also participates in expansion financing and the privatization of small-cap companies, maintaining strong board influence in its investment decisions.

Junghwan Park

Investment Manager

10 past transactions

Rebellions

Series A in 2022
Rebellions Inc specializes in developing artificial intelligence semiconductors that serve as full-stack alternatives for AI processing. The company focuses on creating genuine AI accelerators by effectively linking silicon architectures with deep learning algorithms. This is achieved by pushing the boundaries of algorithms to better utilize silicon resources and redesigning AI processors to include advanced deep learning features through dedicated silicon kernels. Rebellions aims to deliver domain-specific AI processors alongside optimized software, enabling clients to access powerful and energy-efficient AI hardware. Their innovative approach ensures seamless integration and enhanced performance, addressing the limitations of traditional AI chip designs.

Rebellions

Series A in 2022
Rebellions Inc specializes in developing artificial intelligence semiconductors that serve as full-stack alternatives for AI processing. The company focuses on creating genuine AI accelerators by effectively linking silicon architectures with deep learning algorithms. This is achieved by pushing the boundaries of algorithms to better utilize silicon resources and redesigning AI processors to include advanced deep learning features through dedicated silicon kernels. Rebellions aims to deliver domain-specific AI processors alongside optimized software, enabling clients to access powerful and energy-efficient AI hardware. Their innovative approach ensures seamless integration and enhanced performance, addressing the limitations of traditional AI chip designs.

TASTY9

Series B in 2020
Producer and retailer of home meal replacement products intended to provide high-quality and premium food products. The company specializes in various ready-to-eat cuisines like Japanese, Vietnamese and Chinese and also has seasonal food with domestic produce on the menu, enabling working professionals and clients to consume food with ease.

TADA

Series A in 2019
TADA is a zero-commission ride-hailing app that provides safe and friendly service. It is a service where drivers are not charged commissions and are rewarded for providing a safe service. At the same time, TADA passengers will also enjoy reasonable fares for safe rides anytime and anywhere.

Curiox Biosystems

Series B in 2019
Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drug discovery and diagnostics through the miniaturization and improved automation of bioassays.

Oncorus

Series B in 2019
Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

IDS Group

Acquisition in 2007
IDS Group is a provider of asset finance software solutions.

Direct Group

Acquisition in 2004
DG provides a full suite of direct mail services, including printing, letter shop, laser and other personalization, fulfillment, data services and creative consulting through long-term partnerships with world-class customers. The Company has facilities in Swedesboro and Robbinsville, New Jersey, and corporate offices in West Trenton, New Jersey.

Mesa Communications Group

Acquisition in 2002
Mesa Communications Group is a network of clustered community towers designed to accommodate wireless communication operators. It provides tower space to the wireless communications industry. The company develops a network of clustered community towers designed to accommodate wireless communication operators, including broadband wireless carriers, and FM and TV broadcasters, as well as paging, government, and other private land mobile radio operators. Mesa Communications Group was founded in 1999 and is based in Falls Church, Virginia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.